Brian Abrahams

what kinds of signals you'd be looking for there to move forward

if you could maybe talk through the on the ground process of pivoting and redeploying the existing commercial infrastructure ahead of the potential lupus nephrology launches

Can you give us a sense on the early experience with LEQEMBI subcu maintenance uptake and access with regards to non-formulary exceptions

how you educate further around proper patient triage leveraging these new diagnostics

Can you talk about what the rollout strategy could look like there and your sense of what the reimbursement process and amenability could be

elaborate a little bit more on the dynamics you’re seeing in the U.S.? Like are there ways to accelerate patient identification

I was wondering if you could maybe just talk about what you need to show, out of purpose 365 in order to support approval

can you maybe talk bigger picture about what the patient journey is like here for getting an appointment with the physician obtaining and getting Yeztugo administered

a sense of the awareness across the target physician practices of the drug, the number of sites or maybe proportion of your target

if you could elaborate a little bit more on what you're observing in terms of just use pattern prescriber base

if you could maybe tell us about the observations there. And then the scope and dose range that you're going to be testing in this ongoing Phase I study

if you could give us a sense of just the potential volumes and injection times that you're going to be testing for the subcu bioequivalence study

I wanted to unpack the dynamics underlying that. And I'm curious the degree to which pediatric indication is embedded there

can you talk about the role you foresee for that in a post-Jakafi monotherapy setting? And then what's your latest thinking on the frontline development path?

talk about the potential untapped opportunity for systemic biologics here and the degree to which you can broaden the market

I don't want you to front run your roundtable, but I know you guys recently started a large Phase II study

new insights on why the AERIFY-2 study didn't hit its primary endpoint and the feasibility of mitigating that

expectations for annual sales erosion of about 7% annually over the next few years for the EYLEA franchise

With the Povi launch not too far off, what do you think you will need to convey to KOLs and community physicians

if there were any differences such as proportion of patients from China or their degree of patients on SGLT2 inhibitors that might impact proteinuria response